Needham Reiterates Buy on KalVista Pharma, Lowers Price Target to $22
Needham analyst Serge Belanger reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and lowers the price target from $24 to $22.
KalVista Pharmaceuticals Q3 EPS $(0.75) Beats $(0.98) Estimate. Cash And equivalents $171.7M
KalVista Pharmaceuticals (NASDAQ:KALV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.98) by 23.47 percent. This is a 18.48 percent increase over losses of $(0.92) per
Kalvista Pharmaceuticals Announced Phase 3 Konfident Clinical Trial Passes 50% Enrollment Milestone; Topline Data Still Expected In H2 2023
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) , today provided multiple clinical trial and regulatory updates for its lead compound sebetralstat, as a potential oral on-demand therapy for HAE attacks.
Gold Rises Over 1%; Elys Game Technology Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Dow Jones trading slightly higher on Tuesday.
Dow Rises 100 Points; Crude Oil Rises Over 1%
U.S. stocks traded mixed midway through trading, with the Dow Jones gaining around 100 points on Tuesday.
12 Health Care Stocks Moving In Tuesday’s Pre-Market Session
Gainers 180 Life Sciences (NASDAQ:ATNF) stock rose 75.8% to $2.18 during Tuesday’s pre-market session. The company’s market cap…
KalVista Pharmaceuticals Presents Patient-Focused Data At American College of Allergy, Asthma & Immunology 2022 Meeting
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented two posters
KalVista Pharmaceuticals Announces Phase 1 Data For Orally Disintegrating Tablet Formulation Of Sebetralstat For Use In Hereditary Angioedema
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced positive
Stocks That Hit 52-Week Lows On Wednesday
During Wednesday's trading, 517 companies set new 52-week lows.